Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy

Diabetes. 2013 Jan;62(1):36-8. doi: 10.2337/db12-1223.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetic Retinopathy / drug therapy*
  • Fenofibrate / therapeutic use*
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • PPAR alpha / agonists*

Substances

  • Hypoglycemic Agents
  • PPAR alpha
  • Fenofibrate